معرفی
Kelly S. DeMartini, PhD, is a Research Scientist in Psychiatry and Administrative Director of the Center for the Translational Neuroscience of Alcoholism at Yale School of Medicine. Her work focuses on developing technology-based interventions for alcohol use disorders and integrating digital phenotyping through wearable and smartphone technologies. She specializes in addiction medicine, behavioral medicine, and digestive diseases, particularly in treating patients with liver disease and co-occurring alcohol use disorders. Dr. DeMartini’s clinical approach emphasizes personalized, team-based care to address the social stigma and health challenges faced by patients with liver disease.
Dr. DeMartini holds a PhD from Syracuse University and completed postdoctoral training at Yale School of Medicine. She contributes to national initiatives like the Alcoholic Hepatitis Network, shaping clinical trial guidelines for patients with alcoholic liver disease and substance use disorders. Her research spans quantitative modeling of alcohol use trajectories, digital intervention design, and the role of gender in treatment outcomes. Key collaborations include work with Lisa Fucito, John Krystal, and Nancy Schmieder Redeker, among others.
Her recent studies include a randomized controlled trial of a multimodal mobile sleep intervention for young adult drinkers, and a natural language processing evaluation of digital interventions. Dr. DeMartini’s articles explore themes like wearable alcohol monitoring, neurobehavioral phenotypes in heavy drinkers, and integrated behavioral healthcare impacts. She has secured grants from NIAAA and other agencies, advancing translational research at the intersection of addiction, technology, and liver health.
Dr. DeMartini’s lab, the DIGITAL Insights Lab, focuses on leveraging technology to enhance substance use treatment accessibility. She advocates for holistic care integrating biosensor data to improve outcomes for alcohol use disorders and liver-related conditions, reflecting her commitment to bridging clinical practice and innovative research.